

# AndrÃ© Albergaria

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3503959/publications.pdf>

Version: 2024-02-01

31  
papers

1,936  
citations

304743

22  
h-index

434195

31  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2802  
citing authors

#	ARTICLE	IF	CITATIONS
1	Homologous recombination deficiency as prognostic marker in metastatic gastric cancer.. Journal of Clinical Oncology, 2019, 37, 4040-4040.	1.6	2
2	The basal epithelial marker P-cadherin associates with breast cancer cell populations harboring a glycolytic and acid-resistant phenotype. BMC Cancer, 2014, 14, 734.	2.6	25
3	P-cadherin signals through the laminin receptor $\alpha 6 \beta 4$ integrin to induce stem cell and invasive properties in basal-like breast cancer cells. Oncotarget, 2014, 5, 679-692.	1.8	49
4	Clinicopathological significance of ERCC1 expression in breast cancer. Pathology Research and Practice, 2013, 209, 331-336.	2.3	14
5	P-cadherin functional role is dependent on E-cadherin cellular context: a proof of concept using the breast cancer model. Journal of Pathology, 2013, 229, 705-718.	4.5	68
6	p40: A p63 Isoform Useful for Lung Cancer Diagnosis – A Review of the Physiological and Pathological Role of p63. Acta Cytologica, 2013, 57, 1-8.	1.3	52
7	CCAAT/Enhancer Binding Protein $\beta 2$ (C/EBP $\beta 2$ ) Isoforms as Transcriptional Regulators of the Pro-Invasive CDH3/P-Cadherin Gene in Human Breast Cancer Cells. PLoS ONE, 2013, 8, e55749.	2.5	20
8	P-cadherin Is Coexpressed with CD44 and CD49f and Mediates Stem Cell Properties in Basal-like Breast Cancer. Stem Cells, 2012, 30, 854-864.	3.2	64
9	Epithelial E- and P-cadherins: Role and clinical significance in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 297-311.	7.4	137
10	Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast, 2012, 21, 354-360.	2.2	43
11	Molecular phenotypes of matched in situ and invasive components of breast carcinomas. Human Pathology, 2011, 42, 1438-1446.	2.0	10
12	P-cadherin role in normal breast development and cancer. International Journal of Developmental Biology, 2011, 55, 811-822.	0.6	64
13	Nottingham Prognostic Index in Triple-Negative Breast Cancer: a reliable prognostic tool?. BMC Cancer, 2011, 11, 299.	2.6	50
14	Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology, 2010, 56, 860-867.	2.9	168
15	Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene, 2010, 29, 392-402.	5.9	106
16	Co-expression of E- and P-cadherin in breast cancer: role as an invasion suppressor or as an invasion promoter?. BMC Proceedings, 2010, 4, .	1.6	1
17	ICI 182,780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBP $\beta$ in CDH3 gene activation. Human Molecular Genetics, 2010, 19, 2554-2566.	2.9	18
18	P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histology and Histopathology, 2010, 25, 963-74.	0.7	46

#	ARTICLE	IF	CITATIONS
19	Estrogens, MSI and Lynch syndrome-associated tumors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1796, 194-200.	7.4	14
20	Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. <i>Breast Cancer Research</i> , 2009, 11, R40.	5.0	134
21	Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. <i>Oncogene</i> , 2008, 27, 9-19.	5.9	130
22	The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3169-3179.	4.1	77
23	P-cadherin expression in breast cancer: a review. <i>Breast Cancer Research</i> , 2007, 9, 214.	5.0	93
24	P-cadherin expression in glandular lesions of the uterine cervix detected by liquid-based cytology. <i>Cytopathology</i> , 2005, 16, 88-93.	0.7	11
25	P-Cadherin Overexpression Is an Indicator of Clinical Outcome in Invasive Breast Carcinomas and Is Associated with CDH3 Promoter Hypomethylation. <i>Clinical Cancer Research</i> , 2005, 11, 5869-5877.	7.0	236
26	P-Cadherin Expression in Canine Mammary Tissues. <i>Journal of Comparative Pathology</i> , 2004, 130, 13-20.	0.4	22
27	Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast. <i>Cancer</i> , 2003, 99, 172-179.	4.1	51
28	p63 staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast. <i>Journal of Clinical Pathology</i> , 2002, 55, 936-939.	2.0	38
29	Naked nuclei revisited: p63 Immunoexpression. <i>Diagnostic Cytopathology</i> , 2002, 27, 135-138.	1.0	19
30	p63 expression in normal skin and usual cutaneous carcinomas. <i>Journal of Cutaneous Pathology</i> , 2002, 29, 517-523.	1.3	139
31	Maspin expression in normal skin and usual cutaneous carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2002, 441, 551-558.	2.8	35